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Introduction
The organizer of the Advanced and Metastatic Breast Can-
cer Consensus Conferences (ABC) is the ‘European School of 
Oncology’ (ESO). The recommendations of this year’s Sec-
ond ABC Consensus (ABC2) focused on locally advanced 
breast cancer (LABC) and will be published in coordination 
with various international specialist associations, the Euro-
pean Society of Medical Oncology (ESMO), the European 
Society of Mastology (EUSOMA), the Federación Lati-
noamericana de Mastologia (FLAM), and the Senologic In-
ternational Society (SIS) in the journal The Breast at the be-
ginning of 2014.
The goal of the ABC Consensus is the international 
harmonization and standardization of treatment for patients 
with locally advanced and/or metastatic breast cancer. The 
topic of this year’s ABC2 Consensus was inoperable LABC 
without distant metastases. Recommendations for the 
diagnosis and treatment of metastatic breast cancer (stage IV) 
had already been developed as part of the ABC1 Consensus 
Conference in Lisbon in November 2011. Special issues 
concerning the metastatic setting were updated.
The ABC2 panel consisted of 41 experts from 20 countries, 
including 2 representatives from Germany (Nadia Harbeck, 
Christoph Thomssen, table 1). Since every therapy decision 
must consider individual criteria (e.g., patient preference, co-
morbidities, pretreatment, tumor biology, burden of disease) 
in addition to evidence-based data, the ABC panelists delib-
erately do not recommend individual drugs or therapeutic 
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Summary
The Advanced Breast Cancer Second International Con-
sensus Conference (ABC2) on diagnosis and treatment 
of advanced breast cancer took place in Lisbon, Portugal, 
on November 7–9, 2013. The focus of the conference 
was inoperable, locally advanced breast cancer. The di-
agnosis and treatment of metastatic breast cancer had 
already been discussed 2 years before at the ABC1 Con-
sensus and were only updated regarding special issues 
as part of this year’s ABC2 Consensus. Like 2 years ago, 
a working group of German breast cancer experts com-
mented on the voting results of the ABC panelists, with 
special consideration of the German guidelines for the 
diagnosis and treatment of breast cancer (German Gy-
necological Oncology Working Group (AGO) recommen-
dations, S3 Guideline) in order to adapt them for daily 
clinical practice in Germany. The goal of both the ABC 
Consensus and the German comments is to facilitate evi-
dence-based therapy decisions.
Writing committee: Nadia Harbeck, Norbert Marschner, Michael Untch, 
Christoph Thomssen.
ABC Panel Members: Nadia Harbeck, Christoph Thomssen.
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ical examination, and measurement of laboratory values, in-
cluding chest, abdomen, and bones, prior to starting systemic 
therapy (LoE: IB). If computed tomography (CT) and/or 
positron emission tomography (PET)-CT are available, they 
may be used as part of the staging, according to the ABC2 
recommendation (LoE: IIB).
The German experts basically agree but emphasize that the 
medical history and physical and laboratory examinations be 
performed first before any imaging and that conventional pro-
cedures – chest X-ray, abdominal ultrasound, bone scan – 
have priority. The German experts recommend a CT scan of 
the chest primarily for a more precise assessment of loco-
regional tumor spread. They also emphasized that CT exami-
nations of chest and abdomen have a higher sensitivity for 
these high-risk patients. The use of newer imaging procedures 
was discussed. The German experts agreed that new imaging 
procedures, such as PET-CT or whole-body magnetic reso-
nance imaging (WB-MRI), may be more sensitive in individ-
ual cases. Yet, there is currently no evidence that their routine 
use improves patient prognosis.
General Aspects of Therapy
The ABC2 panelists and the German experts agreed that 
patients with primary inoperable LABC initially require 
 systemic treatment before surgery and locoregional radio-
therapy. It was also agreed that the vast majority of patients 
require multimodal treatment, which consists of systemic 
therapy, surgery, and locoregional radiation (LoE: IA). If the 
tumor remains inoperable after systemic treatment plus radia-
tion, palliative mastectomy is discouraged. This does not 
apply if the surgical intervention is assumed to improve the 
patient’s quality of life. The use of autologous tissue flaps for 
covering resection-related tissue defects should also be con-
sidered as an option.
 sequences. Rather, the goal is to establish a basis for individ-
ual, evidence-based therapy decisions. The statements submit-
ted to a recommendation were assessed by the panelists with 
‘yes’ (approval), ‘no’ (rejection) or ‘abstention’. Since the vot-
ing results are based on the opinions of experts from different 
specialties who come from countries with different healthcare 
systems and resources, it seems reasonable to discuss the 
 voting results from the German perspective in order to adapt 
them for daily clinical practice in Germany.
Inoperable LABC
The first part of the ABC2 meeting focused on the diagno-
sis and treatment of inoperable LABC. The German experts 
point out that patients with inoperable LABC may still have 
– in the absence of distant metastases – a chance of cure; 
therefore, standard therapies for the treatment of operable 
primary breast cancer must be considered in this situation. 
Prior to starting therapy, every patient should be discussed in 
a multidisciplinary tumor board.
General Aspects of Diagnosis
There was a high level of agreement among the ABC2 
 panelists in the general statements on the diagnosis of inoper-
able LABC: As the basis for an adequate therapy decision, 
the ABC2 panelists, in agreement with the German experts, 
recommend performing a core needle or a punch biopsy be-
fore start of therapy in order to determine the histology and 
biomarker expression of the breast cancer (level of evidence 
(LoE): IB).
Patients with LABC have a high risk of distant metastasis. 
Therefore, the ABC2 panelists recommend initiating a com-
plete imaging staging, in addition to the medical history, phys-
Table 1: ABC2 Consensus Panelists
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Fig. 1. Consensus Panelists in Lisboa on Saturday morning  
(November 9, 2013).




All ABC2 panelists agree that it is possible and sensible 
for many patients who responded well to neoadjuvant sys-
temic treatment with or without preoperative radiation to 
 undergo subsequent surgery. These patients generally receive 
a mastectomy plus axillary dissection. Breast-preserving sur-
gery is an option in individual cases. The German experts 
agree with this statement.
Inflammatory LABC
The same treatment principles apply to inflammatory 
LABC and non-inflammatory LABC (LoE: IB). The German 
experts extend this statement of the ABC2 panelists by noting 
that neoadjuvant (primary) chemotherapy (NACT) is a man-
datory standard for inflammatory breast cancer.
According to the ABC2 recommendation, patients with in-
flammatory LABC should undergo a modified radical mastec-
tomy. This also applies if they respond well to prior NACT 
(LoE: IB). It has to be noted that the German guidelines even 
allow breast conservation in selected patients with an excel-
lent response (pathologically confirmed complete remission 
(pCR)) to NACT and a limited involvement of skin at first 
presentation (www.ago-online.com). The German experts 
agree with the ABC2 recommendation for patients with clini-
cally detectable involvement of lymph nodes and note that 
axillary treatment for these patients must be based on stand-
ards of NACT. Particularly in inflammatory breast cancer, 
 axillary dissection remains the standard and the modified 
American College of Surgeons Oncology Group (ACOSOG) 
approach should not be applied.
The ABC2 panelists and German experts agree that pa-
tients with inflammatory LABC require locoregional radio-
therapy following mastectomy (LoE: IB). Therefore, the 
ABC2 panelists do not recommend immediate breast recon-
struction following mastectomy (LoE: expert opinion). The 
German experts recommend reconstruction to repair exten-
sive tissue defects after R0 resection.
Therapy Decision Depending  
on the Tumor Biology of LABC
Triple-Negative LABC
With a clear majority, the ABC2 panelists recommend an-
thracycline- and taxane-based chemotherapy as initial treat-
ment for patients with triple-negative inoperable LABC (es-
trogen receptor-negative (ER–), progesterone receptor-nega-
tive (PR–), human epidermal growth factor receptor 2-nega-
tive (HER2–) LABC) (LoE: IA). The German experts agree 
and add that the established standard anthracycline- and tax-
ane-containing regimens are recommended for triple-negative 
LABC. If a BRCA mutation is detected, the additional use of 
a platinum-containing regimen can be considered.
BRCA-Mutated Metastatic Breast Cancer
In a separate recommendation on BRCA-mutated meta-
static breast cancer, the ABC2 panelists supported the use of 
platinum-based therapy outside of clinical trials for patients 
with either endocrine-resistant or triple-negative cancer if 
they have already been pretreated with anthracyclines and 
taxanes (adjuvant or metastatic) (LoE: IC). The ABC2 pan-
elists note that poly(ADP-ribose) polymerase (PARP) inhibi-
tors have been very effective in clinical trials in cases of 
BRCA-mutated breast cancer. But regardless of this, the 
ABC2 panelists state that the therapy recommendations for 
sporadically metastatic breast cancer currently apply for 
BRCA-mutated metastatic breast cancer. The German ex-
perts agree and recommend participation in the upcoming 
clinical trials with PARP inhibitors.
HER2-Positive LABC
The majority of the ABC2 panelists recommend concomi-
tant treatment with taxanes and an anti-HER2 therapy for the 
treatment of patients with HER2-positive inoperable LABC, 
since concomitant administration is associated with a higher 
rate of pCRs (LoE: IA). The German experts agree and 
note that this is consistent with the German guidelines 
(www.awmf.org, www.ago-online.de).
If the patient also receives an anthracycline, this should be 
integrated sequentially in the regimen (LoE: IA). If an anti-
HER2 drug and anthracyclines are administered concomi-
tantly, the pCR rate is not increased, but the risk of cardiac 
adverse events is higher (LoE: IB).
The German experts recommend to generally use anthra-
cyclines (in combination with cyclophosphamide) followed by 
taxane and trastuzumab-containing combination therapy – as 
a rule. The German experts explain this approach with the 
 potentially increased risk of cardiac toxicities under concomi-
tant administration of trastuzumab with the anthracycline, 
 although in the neoadjuvant clinical trials with trastuzumab 
given concomitantly with the anthracycline (e.g. ACOSOG 
Z1041, Geparquattro, NOAH) a clinically relevant increase 
of cardiotoxicity has so far not been observed. Nevertheless, it 
could not be excluded if used widely in clinical routine. Thus, 
in the absence of a higher pCR rate, this concomitant sched-
ule is not justified from the German perspective (ACOSOG 
Z1041 study) [1]. The German experts point out that a sub-
stantial increase in the pCR rate can be achieved by dual 
HER2 blockade with trastuzumab plus pertuzumab or trastu-
zumab plus lapatinib.
ER-Positive LABC
For patients with hormone-sensitive (ER-positive) LABC, 
both anthracycline-/taxane-based chemotherapy and endo-
crine treatment alone are available as therapeutic options 
(LoE: IA). The decision must be made depending on the pa-
tient’s individual situation (general condition, comorbidities, 
preference) and the tumor characteristics (grade, biomarker 
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 experts consider talc instillation (with video-assisted thora-
coscopy (VATS)) for pleurodesis as the most effective pallia-
tive treatment option for patients with pleural effusion at this 
time and also recommend a cytological confirmation, if possi-
ble with determination of biomarkers (ER, PR, HER2). How-
ever, there are also reports in the current literature on con-
tinuous drainages in the outpatient setting.
Chest Wall and Locoregional Recurrence
Patients with a chest wall and/or locoregional recurrence 
(with involvement of lymph nodes) have a high risk of distant 
metastasis. The ABC2 panelists therefore recommend com-
plete restaging with an evaluation of the lung, abdomen, and 
bones (LoE: expert opinion). The German experts agree with 
the panelists but add that, similar to the situation during the 
initial diagnosis, the medical history plus a clinical examina-
tion must precede the staging and that conventional imaging 
(chest X-ray, upper-abdomen sonography or CT, as well as 
bone scans) must be the initial focus (see above).
There was agreement that patients with a chest wall and/or 
locoregional recurrence should undergo surgery if this ap-
proach is feasible with low morbidity. In addition, the patients 
require locoregional radiation treatment if they were not pre-
viously irradiated (LoE: IB). However, in individual cases, re-
peated radiation of the chest wall or certain regions may also 
be considered (LoE: expert opinion).
The German experts point out that a R0 resection should 
be the goal of the surgical intervention. Thus, if required, ex-
tensive resection with subsequent repair using autologous tis-
sue should also be considered. In this context, the German 
experts note that the tumor volume can also be reduced pre-
operatively by using preoperative systemic treatment. If a re-
radiation is performed, concomitant local hyperthermia can 
induce an improved local control. German centers offering 
this procedure are listed on the homepage of the German 
Cancer Society (DKG).
The vast majority of the ABC2 panelists recommended 
that patients with a chest wall and/or locoregional recurrence 
should also receive ‘pseudo-adjuvant’ systemic treatment fol-
lowing radical surgery and/or radiation (LoE: IB). Systemic 
treatment may consist of chemotherapy, endocrine treatment 
and/or anti-HER2 therapy. The choice of systemic treatment 
depends on different factors, like receptor status, pretreat-
ment, and duration of the disease-free interval. ‘Secondary 
adjuvant’ chemotherapy has the best results in patients with 
an ER-negative recurrence.
The German experts note that the term ‘pseudo-adjuvant’ 
is not routinely used in Germany and prefer the term ‘second-
ary adjuvant’ systemic therapy. They also note that chemo-
therapy can be used preoperatively.
The ABC2 panelists and the German experts agreed that 
palliative systemic therapy based on therapeutic principles for 
the metastatic setting is appropriate for those patients for 
whom radical local therapy is not an option or is declined.
expression). The German experts add that the patient’s meno-
pausal status should also be considered in the therapy deci-
sion, and point out that endocrine treatment alone is reserved 
for individual situations, e.g., for clinically relevant comorbid-
ity. The German experts emphasize that the use of chemo-
therapy is usually recommended in view of the still potentially 
curative setting.
Special Metastatic Breast Cancer Settings
Focus on Liver Metastases
The question cannot be answered whether and when pa-
tients with liver metastases will benefit from local treatment. 
The majority of the ABC2 panelists agreed that prospective 
clinical trials are urgently needed, since evidence-based data 
have up to now been available only for selected individual pa-
tient groups. Therefore, according to the consensus recom-
mendation of the ABC2 panelists, the therapeutic decision 
must be discussed in an interdisciplinary team (tumor board). 
If there is the possibility to participate in a clinical trial, this 
should be preferred.
Therefore, local therapies are currently options for indi-
vidual cases only. Candidates should have a good perfor-
mance status, only limited metastasis in the liver, and no or 
well-controlled extrahepatic lesions. In the absence of rele-
vant data, it is currently unclear which local treatment is the 
most appropriate one for each individual patient (LoE: expert 
opinion).
The German experts agree with the statement of the 
ABC2 panelists, emphasize the importance of an inter-
disciplinary board and underline that the local approach 
must  remain reserved for individual patients who are in a 
 stable disease situation under systemic treatment. Non- 
surgical,  locally ablative approaches such as laser-induced 
thermotherapy (LITT), selective internal radiation therapy 
(SIRT), transarterial chemo embolization (TACE), or radio-
frequency ablation (RFA) may also be considered in individ-
ual cases.
Focus on Malignant Pleural Effusion
The majority of the ABC2 panelists recommend systemic 
and local treatment for patients with malignant pleural effu-
sion. Despite a relatively high rate of false-negative results, 
they advocate thoracocentesis for diagnostic purposes. They 
recommend drainage for symptomatic patients with clinically 
relevant (moderate to massive) pleural effusion. In addition, 
talcum or cytostatic drugs, e.g. bleomycin, may be helpful for 
pleurodesis (LoE: II B).
The German experts advocate a palliative thoracocentesis 
only for symptomatic patients. As long as the patient’s disease 
is stable, local treatment of a malignant pleural effusion for 
palliative reasons may be sufficient initially. In this case, a 
change of systemic therapy is not necessary. The German 




valid therapy option for patients with hormone receptor-posi-
tive metastatic breast cancer and endocrine resistance. The 
addition of everolimus to exemestane in the pivotal BO-
LERO-2 trial [2] resulted in a clinically meaningful extension 
of the median progression-free survival by approximately 
5 months. Overall survival data are not yet available; there-
fore, the therapy decision should also take into account the 
increased toxicity associated with everolimus (LoE: IB). In 
addition, it should be noted that there are still no predictive 
biomarkers to identify those patients who benefit most from 
this approach.
The German experts basically agree with this statement. 
They also point out that the indication for adding everolimus 
to the aromatase inhibitor should be in line with the inclusion 
criteria of the BOLERO-2 trial [2]. The German experts em-
phasize that it is necessary to balance treatment benefits with 
the potentially increased toxicity compared to endocrine ther-
apy alone.
HER2 Blockade in HER2-Positive  
Metastatic Breast Cancer
For patients with HER2-positive metastatic breast cancer, 
the combination of chemotherapy plus trastuzumab is supe-
rior to the combination of chemotherapy plus lapatinib with 
respect to progression-free and overall survival. This applies 
regardless of whether patients are already pretreated with 
trastuzumab or not (LoE: IA). The majority of the ABC2 
panelists agree with this statement. The German experts con-
firm that this statement is consistent with current data and 
point out that new evidence has been provided by the MA.31 
[3] and the CEREBEL studies since ABC1 [4].
The majority of the ABC2 panelists recommend dual 
HER2 blockade with trastuzumab plus pertuzumab (in addi-
tion to taxane chemotherapy) as the preferred therapy option 
for first-line treatment (LoE: 1A), especially for patients with-
out any anti-HER2 pretreatment. Current data from the 
CLEOPATRA study [5, 6] show that dual HER2 blockade 
with pertuzumab plus trastuzumab plus docetaxel is superior 
to the combination of trastuzumab plus docetaxel with regard 
to progression-free and overall survival. The German experts 
agree since this recommendation is in line with the updated 
German Gynecological Oncology Working Group (Arbeits-
gemeinschaft gynäkologische Onkologie (AGO)) guidelines 
(www.ago-online.de). From the German perspective, dual 
HER2 blockade with pertuzumab plus trastuzumab together 
with docetaxel chemotherapy is a new standard for first-line 
therapy of HER2-positive metastatic breast cancer.
The ABC2 panelists and the German experts also agree on 
the following items: At this time it is still unclear how the new 
dual HER2 blockade performs compared to other anti-
HER2-based therapy options, e.g., compared to the antibody-
drug conjugate trastuzumab emtansine (T-DM1). There are 
currently no data to support routine use of dual HER2 block-
ade with pertuzumab plus trastuzumab in later therapy lines 
Updates Regarding Metastatic Breast Cancer
Focus on the Patient
It is indisputable that all patients with advanced breast can-
cer must be fully informed about their disease and the treat-
ment options. This must not only be done in an understanda-
ble way and reflect current scientific knowledge, but should 
also be realized with empathy and in consideration of the cul-
tural background. The German experts add that the therapy 
decision will be made together with the informed patient 
(‘shared decision-making’).
The majority of the ABC2 panelists recommended to sur-
vey patients routinely with validated questionnaires regarding 
tumor-related complaints and therapy-related adverse events. 
This should be a regular component of the clinical manage-
ment. The ABC2 panelists view such systematic monitoring as 
the basis for
– facilitating communication between patient and treatment 
team,
– guaranteeing the best-possible quality of life for the patient,
– better recognizing and characterizing toxicities of treat-
ment. The last item is particularly important for newly 
 approved drugs/therapies, especially for those whose ap-
proval is based only on an advantage in progression-free 
survival or on a moderate survival advantage (LoE: IC).
The German experts point out that regular recording of ad-
verse events is part of standard oncological care in Germany 
and that adverse events are documented in the medical re-
cords. Recording using validated questionnaires and subse-
quent evaluation on a routine basis is desirable in principle 
but not feasible in clinical daily routine. The requirement to 
work routinely with validated questionnaires in daily clinical 
practice is therefore unrealistic and remains reserved primar-
ily for patients in clinical trials.
There is agreement/consensus among the ABC panelists 
and the German experts that the patient’s age in and of itself 
should not be the decisive factor for the choice of therapy 
 decision. On the one hand, older patients should not be 
 excluded from effective standard therapy just because of their 
age. On the other hand, aggressive treatment should not be 
triggered solely by young age (risk of overtreatment) (LoE: 
IB).
Integration of Specialized Nurses
The German experts agree with the recommendation of 
the ABC2 panelists that specialized oncology nurses, if possi-
ble specialized breast care nurses, should be part of the inter-
disciplinary treatment team (LoE: expert opinion). In Ger-
many, specialized breast care nurses are mandatory team 
members in all certified breast centers.
ER-Positive/HER2-Negative Metastatic Breast Cancer
A clear majority of the ABC2 panelists agree that the com-
bination of everolimus plus aromatase inhibitors can be a 
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 (either trastuzumab or lapatinib) in combination with endo-
crine therapy has shown substantial progression-free survival 
benefit (i.e. ‘time without CT’) even though no survival bene-
fit compared to endocrine therapy alone (LoE: 1 A). This 
 approach may be an option for patients with oligo-metastatic 
disease or comorbidities.
Brain Metastases in Patients with  
HER2-Positive Breast Cancer
The survival time of patients with HER2-positive breast 
cancer and brain metastases has improved in recent years. 
A clear majority of the ABC2 panelists therefore recom-
mended to pay particular attention to the toxicity of treat-
ment and to use (if possible) less toxic local treatments, e.g., 
stereotactic radiation.
The German experts note that the therapeutic standards 
for the treatment of brain metastases apply regardless of the 
HER2 status and should be followed. In addition to neurosur-
gical treatments and total brain radiation, stereotactic radia-
tion can also be an option. In general, the German experts 
recommend total brain radiation.
HER2-Negative Metastatic Breast Cancer
A majority of the ABC2 panelists recommended that the 
preferred endocrine first-line treatment for postmenopausal 
patients with HER2-negative and ER-positive metastatic 
breast cancer is either an aromatase inhibitor or tamoxifen. 
The therapy decision depends on the type and duration of the 
adjuvant endocrine pretreatment (LoE: IA). High doses of 
fulvestrant are an alternative (LoE: IB). The German experts 
refer to the current AGO guidelines (www.ago-online.de) for 
the therapy decisions and confirm that the optimal individual 
first-line endocrine therapy is based on the duration and type 
of pretreatment (tables 2 and 3).
For patients with HER2-negative metastatic breast cancer 
who have been pretreated with anthracyclines and taxanes 
and do not require combination chemotherapy, the ABC2 
panelists consider cytostatic monotherapy with capecitabine, 
vinorelbine, carboplatin, or eribulin as the preferred therapy 
(i.e. after first-line treatment). The German experts add that 
there are also no data on the repeated use of dual HER2 
blockade with the same anti-HER2 agents across multiple 
lines, i.e. treatment beyond progression (TBP).
The ABC2 panelists evaluated the antibody-drug conju-
gate T-DM1 after failure of the trastuzumab-containing first-
line therapy as the most effective option for the subsequent 
therapy lines (LoE: IA) [7, 8]. The German experts agree with 
this statement.
According to the ABC2 panelists, it is basically unclear at 
this time which therapy option is the best one for metastatic 
patients with HER2-positive breast cancer and recurrence 
 following adjuvant anti-HER2-containing treatment. Yet, it is 
undisputed that patients require another line of anti-HER2-
based treatment (LoE: IB). Finally, the ABC2 panelists state 
that the choice of the anti-HER2-based regimen depends on 
the circumstances in the particular country and the available 
drugs, as well as on the anti-HER2-based pretreatment and 
the length of the recurrence-free interval. The optimal se-
quence of available anti-HER2-based therapies is still unclear 
at the moment [9].
The German experts recommend that patients who do not 
have a recurrence or metastasis for more than 1 year after the 
end of adjuvant trastuzumab administration can receive first-
line treatment with pertuzumab plus trastuzumab plus doc-
etaxel, in accordance with the CLEOPATRA study [5, 6]. 
The optimal further treatment for patients with early metasta-
sis or only a short recurrence-free period (< 1 year after the 
end of adjuvant trastuzumab) is unclear. From the German 
perspective, the following options are possible: T-DM1, 
capecitabine plus lapatinib, taxane plus trastuzumab plus per-
tuzumab, and trastuzumab plus lapatinib. With regard to the 
optimal sequence, the German experts refer to the respective 
approval status. They also point out that ABC1 recommended 
that in patients with ER+ and HER2+ metastatic breast can-
cer for whom endocrine therapy was chosen over chemother-
apy, anti-HER2 plus endocrine therapy should be considered 
with the initiation of endocrine therapy (provided that further 
anti-HER2 therapy is available) since anti-HER2 therapy 
Treatment sequence Oxford LoE / AGO GR
First line aromatase inhibitors (3rd generation)a 1a A ++
fulvestrant 250 mg + anastrozole 1b B ±
Second line fulvestrant 2b B
fulvestrant 500 mg 2b B ++
fulvestrant 250 mg 1b B +
exemestane + everolimus 1b B ++
tamoxifen 3b C +
aromatase inhibitorsb 2b B +
tamoxifen + everolimus 2b B +
Other therapy lines MPA / MA 4 D +
estradiol 6 mg daily 3b C +
reinduction of previous therapies 5 D +
aThere is no evidence of the superiority of an individual aromatase inhibitor.
bSteroidal or non-steroidal aromatase inhibitor, depending on the previous one.
GR = Grade of recommendation, MPA = medroxyprogesterone acetate, MA = megestrol acetate.
Table 2. Endocrine therapy of postmeno-
pausal, hormone receptor-positive, HER2-
negative metastatic breast cancer following 
adjuvant tamoxifen therapy or without 
 adjuvant endocrine therapy (modified from 
www.ago-online.de)




breast cancer, as progression within 6 months after the start of 
ongoing first-line endocrine treatment. The majority of the 
ABC2 panelists define acquired (secondary) endocrine resist-
ance for early breast cancer as recurrence during adjuvant en-
docrine therapy after more than 2 years or within 1 year after 
the end of adjuvant endocrine treatment. In the opinion of the 
ABC2 panelists, secondary endocrine resistance in metastatic 
breast cancer is assumed if there is progression only after 
more than 6 months after start of the current endocrine 
treatment.
The German experts note that endocrine resistance devel-
ops continuously; therefore, an arbitrary differentiation be-
tween primary and secondary resistance is clinically difficult. 
The German experts emphasize that starting a different endo-
crine therapy after endocrine failure generally makes sense in 
daily clinical practice, regardless of the time of progression in 
case of a positive hormone receptor status. Chemotherapy is 
primarily indicated only for rapidly progressing disease with 
symptoms that require a fast therapy response.
ABC Patient Advocacy Committee
At this years’ ABC meeting, breast cancer advocacy organ-
izations (n = 49) met separately from the scientific session, 
and a report from the ABC Patient Advocacy Committee was 
presented during the plenary consensus. The committee em-
phasized the need for multidisciplinary team (MDT) discus-
sions using ABC-specific guidelines, patient navigators, conti-
nuity of oncologists and nurses in patient care, improved com-
munication between the patients and the MDT, as well as 
knowledge and consideration of the patients’ priorities. Other 
issues to be considered include supportive care for the pa-
tients themselves, their families and caregivers, and nutrition, 
sexual dysfunction, complementary medicine, and rehabilita-
tion. The different national healthcare systems need to enable 
easy access to clinical trials, standardized and affordable treat-
option. When choosing a therapy, the differences in the side 
effect profile of the drugs should be considered (LoE: IB). 
The German experts agree and add that repeated administra-
tion (re-challenge) of a taxane (e.g., docetaxel, nab-paclitaxel, 
or paclitaxel – whatever had not been given in the early breast 
cancer setting) or an anthracycline such as (peg-)liposomal 
doxorubicin are also valid options for cytostatic monotherapy. 
However, they also point out that there is not sufficiently vali-
dated data to support monotherapy with gemcitabine in meta-
static breast cancer.
Male Breast Cancer
Male breast cancers are generally hormone sensitive (posi-
tive hormone receptor status). Therefore, endocrine thera-
peutic treatments, preferably with tamoxifen, are the therapy 
of choice. If an aromatase inhibitor is used, it should be given 
with a luteinizing hormone-releasing hormone (LHRH) ago-
nist; an alternative to the LHRH agonist is an orchiectomy. 
Exclusive aromatase inhibitor therapy is an option if the pa-
tient’s response to therapy is closely monitored. The ABC2 
panelists and the German experts agree on these points and 
note the urgent need for clinical trials for men with breast 
cancer (such as the ongoing GBG MALE trial, www.german-
breastgroup.de) to answer this as well as other open 
questions.
Focus on Endocrine Resistance
There was an intense debate in Lisbon on primary and sec-
ondary endocrine resistance of the tumor and how to define 
them. The German experts do not agree with the definitions 
of the ABC2 Consensus, where primary endocrine resistance 
for early breast cancer is defined as recurrence within the first 
2 years of adjuvant endocrine therapy and, for metastatic 
Table 3. Endocrine therapy of postmenopausal, hormone receptor-positive, HER2-negative metastatic breast cancer following adjuvant therapy with 
an aromatase inhibitor (modified from www.ago-online.de)
Treatment sequence Oxford LoE / AGO GR
First line tamoxifen 2b B ++
fulvestrant 500 mg 1b B ++
exemestane + everolimusa (recurrence < 1 year) 1b B ++
steroidal aromatase inhibitor after non-steroidal one/non-steroidal  
aromatase inhibitor after steroidal one
2b B +
tamoxifen + everolimus 2b B +
Second line fulvestrant 500 mg 1b B ++
exemestane + everolimus* 1b B ++
tamoxifen (if tamoxifen naive) 5 D +
tamoxifen + everolimus 2b B +
Other therapy lines MPA / MA 4 C +
reinduction of previous therapies 5 D ±
aAfter pretreatment with at least one non-steroidal aromatase inhibitor (metastatic and/or adjuvant).
GR = Grade of recommendation, MPA = medroxyprogestrone acetate, MA = megestrol acetate.
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is already scheduled for November 5–7, 2015. In Germany, 
the updated AGO guidelines will be presented in Frankfurt 
on March 1, 2014.
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ment standards, compliance monitoring, and development of 
tumor banks and patient registries. Last but not least, further 
economic and social needs were mentioned such as maintain-
ing employment, disability coverage, stigmatization due to 
ABC, and the need for support regarding cancer- or therapy-
related lifestyle changes. Since patient advocates are also part 
of the ABC consensus panel, all of these issues will be consid-
ered upon finalization of the official ABC slide set and 
manuscript.
Altogether, the ABC2 was a very informative discussion of 
recent developments in breast cancer. The ABC consensus is 
therefore a good addition to the St. Gallen Conference. ABC3 
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